Resolving Ethical Issues in Stem Cell Clinical Trials: The Example of Parkinson Disease

Soldner F. Hockemeyer D. , “Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors,” Cell 136, no. 5 (2009): 964–77.

Dresser R. , When Science Offers Salvation: Patient Advocacy and Research Ethics (New York: Oxford University Press, 2001).

Amariglio N. Hirshberg A. , “Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient,” PLoS Medicine 6, no. 2 (2009): e1000029.

Hyun I. Lindvall O. , “New Isscr Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research,” Cell Stem Cell 3, no. 6 (2008): 607–9; Lo B. Kriegstein A. Grady D. , “Clinical Trials in Stem Cell Transplantation: Guidelines for Scientific and Ethical Review,” Clinical Trials 5, no. 5 (2008): 517–22; Mathews D. J. Sugarman J. , “Cell-Based Interventions for Neurologic Conditions: Ethical Challenges for Early Human Trials,” Neurology 71, no. 4 (2008): 288–293.

Poewe W. , “Treatments for Parkinson Disease – Past Achievements and Current Clinical Needs,” Neurology 72, no. 7 Supp. (2009): S65–S73.

Benabid A. L. Chabardes S. Mitrofanis J. Pollak P. , “Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease,” Lancet Neurology 8, no. 1 (2009): 67–81; Weaver F. M. Follett K. , “Bilateral Deep Brain Stimulation vs. Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial,” JAMA 301, no. 1 (2009): 63–73.

Freed C. R. Greene P. E. , “Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease,” N. Engl. J. Med. 344, no. 10 (2001): 710–9; Olanow C. W. Goetz C. G. , “A Double-Blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson's Disease,” Annals of Neurology 54, no. 3 (2003): 403–14.

Id.

Braak H. Del Tredici K. , “Assessing Fetal Nerve Cell Grafts in Parkinson's Disease,” Nature Medicine 14, no. 5 (2008): 483–485; Kordower J. H. Chu Y. , “Lewy Body-Like Pathology in Long-Term Embryonic Nigral Transplants in Parkinson's Disease,” Nature Medicine 14, no. 5 (2008): 504–506; Li J. Y. Englund E. , “Lewy Bodies in Grafted Neurons in Subjects with Parkinson's Disease Suggest Host-to-Graft Disease Propagation,” Nature Medicine 14, no. 5 (2008): 501–503; Mendez I. Vinuela A. , “Dopamine Neurons Implanted into People with Parkinson's Disease Survive without Pathology for 14 Years,” Nature Medicine 14, no. 5 (2008): 507–509.

Bodeen C. Zagier A. S. , “China Offers Unproven Medical Treatments,” San Francisco Chronicle, January 6 2008, A17; Enserink M. , “Selling the Stem Cell Dream,” Science 313, no. 5784 (2006): 160–163; Padma T. V. , “Unchecked by Guidelines, Indian Stem Cell Scientists Rush Ahead,” Nature Medicine 12, no. 1 (2006): 4.

Dobkin B. H. Curt A. Guest J. , “Cellular Transplants in China: Observational Study from the Largest Human Experiment in Chronic Spinal Cord Injury,” Neurorehabilitation & Neural Repair 20, no. 1 (2006): 5–13.

Id.

See Freed , supra at note 7.

Council for International Organizations of Medical Sciences, “Cioms International Ethical Guidelines for Biomedical Research Involving Human Subjects, Revised Draft,” available at <http://www.cioms.ch/frame_guidelines_january_2002.htm> (last visited April 5, 2010); National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Biomedical and Behavioral Research (Washington, D.C.: U.S. Government Printing Office, 1979); World Medical Association, “Declaration of Helsinki,” avaialable at <http://www.wma.net/e/ethicsunit/helsinki.htm> (last visited April 5, 2010).

Protection of Human Subjects, 45 Cfr 46 (2005), available at <http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm> (last visited April 5, 2010).

Lo B. , Ethical Dilemmas in Clinical Research: A Practical Guide, (Philadelphia: Lippincott Williams & Wilkins, 2009).

Joffe S. Cook E. F. , “Quality of Informed Consent in Cancer Clinical Trials: A Cross-Sectional Survey,” Lancet 358, no. 9295 (2001): 1772–1777.

Appelbaum P. S. Lidz C. W. , “The Therapeutic Misconception,” in Emanuel E. J. , ed., The Oxford Textbook of Clinical Research Ethics (New York: Oxford University Press, 2008): 633–644; Lidz C. W. Appelbaum P. S. Grisso T. Renaud M. , “Therapeutic Misconception and the Appreciation of Risks in Clinical Trials,” Social Science Medicine 58, no. 9 (2004): 1689–1697.

Henderson G. E. Davis A. M. , “Uncertain Benefit: Investigators' Views and Communications in Early Phase Gene Transfer Trials,” Molecular Therapy 10, no. 2 (2004): 225–31.

See Lo , supra note 16.

Id.

Id.

See Weaver , 2009; Benabid , 2009, supra note 6.

See Lo , supra note 16.

Horng S. H. Miller F. G. , “Placebo-Controlled Procedural Trials for Neurological Conditions,” Neurotherapeutics 4, no. 3 (2007): 531–6.

Macklin R. , “The Ethical Problems with Sham Surgery in Clinical Research,” New England Journal of Medicine 341, no. 13 (1999): 992–6.

See Horng , supra note 25.

Kim S. Y. Frank S. , “Science and Ethics of Sham Surgery: A Survey of Parkinson Disease Clinical Researchers,” Archives of Neurology 62, no. 9 (2005): 1357–1360.

Frank S. A. Wilson R. , “Ethics of Sham Surgery: Perspective of Patients,” Movement Disorders 23, no. 1 (2008): 63–68.

See Weaver , 2009 and Benabid , 2009, supra note 6.

Fleming T. R. Prentice R. L. Pepe M. S. Glidden D. , “Surrogate and Auxiliary Endpoints in Clinical Trials, with Potential Applications in Cancer and Aids Research.” Statistics in Medicine 13, (1994): 955–68.

See Freed , supra note 7.

Arkin L. M. Sondhi D. , “Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders,” Human Gene Therapy 16, no. 9 (2005): 1028–1036.

See Lo , supra note 4.

Lindvall O. Kokaia Z. , “Prospects of Stem Cell Therapy for Replacing Dopamine Neurons in Parkinson's Disease,” Trends in Pharmacological Sciences 30, no. 5 (2009): 260–267.

Institute of Medicine, Responsible Research: A Systems Approach to Protecting Research Participants (Washington, D.C.: National Academies Press, 2003).

National Academy of Sciences, “Guidelines for Human Embryonic Stem Cell Research,” National Academy Press, available at <http://books.nap.edu/catalog.php?record_id=11278> (last visited April 5, 2010).

National Institutes of Health, “Notice of Actions under the Nih Guidelines for Rsearch Involving Recombinant DNA Molecules,” Federal Register 65 (2000): 60627–332.

Scharschmidt T. Lo B. , “Clinical Trial Design Issues Raised During Recombinant DNA Advisory Committee Review of Gene Transfer Protocols,” Human Gene Therapy 17, no. 4 (2006): 448–454.

National Cancer Institute, “The Central Institutional Review Board Initiative,” available at <http://www.ncicirb.org/> (last visited April 5, 2010).

Biomedical Research Alliance of New York, available at <http://www.brany.com/> (last visited April 5, 2010); Multicenter Academic Centers Research Organization, available at <http://www.med.upenn.edu/ohr/aboutmacro.html> (last visited April 5, 2010).

Tully S. , “The Party's Over,” Fortune, June 26 2000, 156.

Steinbrook R. , “The Gelsinger Case,” in Emanuel , supra note 18, at 110–120.

See Lo , supra note 4.

Berg J. W. Lidz C. W. Appelbaum P. S. , Informed Consent: Legal Theory and Clinical Practice, 2nd ed. (New York: Oxford University Press, 2001).

See Lo , supra note 4.

Woodsong C. Karim Q. A. , “A Model Designed to Enhance Informed Consent: Experiences from the Hiv Prevention Trials Network,” American Journal of Public Health 95, no. 3 (2005): 412–9.

National Bioethics Advisory Commission, Ethical and Policy Issues in Research Involving Human Participants (Rockville, MD: National Bioethics Advisory Commission, 2001).

See Hyun , 2007 and Lo , 2008, supra note 4.

See Steinbrook , supra note 43; Couzin J. Kaiser J. , “Gene Therapy: As Gelsinger Case Ends, Gene Therapy Suffers Another Blow,” Science 307, no. 5712 (2005): 1028; Fox R. C. Swazey J. P. , Spare Parts (New York: Oxford University Press, 1992).

Lo B. Field M.J. , Conflicts of Interest in Medical Research, Education, and Clinical Practice (Washington, D.C.: National Academies Press, 2009).

Wood A. J. , “Progress and Deficiencies in the Registration of Clinical Trials.” N. Engl. J. Med. 360, no. 8 (2009): 824–30.

Id.